Zydus Pharmaceuticals (USA) Inc FDA Inspection Record

FEI 3008444937 · Inspections, Form 483s, warning letters and import refusals

Zydus Pharmaceuticals (USA) Inc is an FDA-inspected facility (FEI 3008444937) located in Pennington, NJ, US. RegDataLab tracks 5 FDA inspections at this facility.

What FDA found at this site

Latest inspection
Feb 27, 2020: No Action Indicated (NAI)
Inspections on record
5 (1 VAI, 4 NAI)
Last OAI inspection
None on record
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
55, latest Oct 1, 2026
Import refusals
6

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Feb 27, 2020No Action Indicated (NAI)No citations listed
May 15, 2014No Action Indicated (NAI)No citations listed
Feb 22, 2011Voluntary Action Indicated (VAI)Failure to review ADE information (21 CFR 314.80(b))
Jun 14, 2010No Action Indicated (NAI)No citations listed
Aug 11, 2009No Action Indicated (NAI)No citations listed

Recalls

Showing the 10 most recent of 55 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Oct 1, 2026Class IID-0039-2027Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial, 1 Vial, Rx Only…
Failed Impurities/Degradation Specifications.
Aug 5, 2026Class IID-0745-2026Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by…
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Apr 29, 2026Class IID-0544-2026Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus… and 1 more product
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Mar 9, 2026Class IID-0400-2026Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by…
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Dec 30, 2025Class IID-0295-2026Icosapent Ethyl capsules, 1 gram, 120-count bottles, Rx only, Manufactured by: Softgel…
Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules
Dec 19, 2025Class IIID-0247-2026traZODONE Hydrochloride Tablets, USP, 100mg, 1,000 Tablets, Rx only, Manufactured by…
Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.
Oct 23, 2025Class IID-0159-2026Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured…
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine…
Oct 22, 2025Class IID-0152-2026clomiPRAMINE Hydrochloride, Capsules, USP, 25 mg, packaged in a) 30-count bottles (NDC… and 2 more products
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso…
Sep 24, 2025Class IID-0001-2026Entecavir Tablets, USP, 0.5 mg, 30-count bottle, Rx Only, Manufactured by: Zydus… and 1 more product
Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity
Sep 4, 2025Class IID-0656-2025Entecavir Tablets, USP, 0.5 mg, 30 Tablets, Rx Only, Manufactured by: Zydus Lifesciences… and 1 more product
Failed Impurity/Degradation Specifications

FDA record score

91 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 16, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

44 records behind this number
RecordDatePoints x age weightAdds
Class II recall D-0039-2027, this FEI as the recalling firmOct 1, 20264 x 14
Class II recall D-0745-2026, this FEI as the recalling firmAug 5, 20264 x 14
Class II recall D-0544-2026, this FEI as the recalling firmApr 29, 20264 x 14
Class II recall D-0400-2026, this FEI as the recalling firmMar 9, 20264 x 14
Class II recall D-0295-2026, this FEI as the recalling firmDec 30, 20254 x 14
Class II recall D-0159-2026, this FEI as the recalling firmOct 23, 20254 x 14
Class II recall D-0152-2026, this FEI as the recalling firmOct 22, 20254 x 14
Class II recall D-0001-2026, this FEI as the recalling firmSep 24, 20254 x 14
Class II recall D-0656-2025, this FEI as the recalling firmSep 4, 20254 x 14
Class II recall D-0630-2025, this FEI as the recalling firmSep 3, 20254 x 14
Class II recall D-0623-2025, this FEI as the recalling firmAug 27, 20254 x 14
Class II recall D-0497-2025, this FEI as the recalling firmMay 30, 20254 x 14
Class II recall D-0442-2025, this FEI as the recalling firmMay 13, 20254 x 14
Class II recall D-0361-2025, this FEI as the recalling firmApr 3, 20254 x 14
Class II recall D-0310-2025, this FEI as the recalling firmMar 21, 20254 x 14
Class II recall D-0255-2025, this FEI as the recalling firmFeb 13, 20254 x 14
Class I recall D-0315-2021, this FEI as the recalling firmFeb 18, 202115 x 0.253.8
Class II recall D-0600-2024, this FEI as the recalling firmJun 27, 20244 x 0.62.4
Class II recall D-0617-2024, this FEI as the recalling firmJun 21, 20244 x 0.62.4
Class II recall D-0096-2024, this FEI as the recalling firmOct 19, 20234 x 0.62.4
Class II recall D-0038-2024, this FEI as the recalling firmSep 21, 20234 x 0.62.4
Class II recall D-1351-2022, this FEI as the recalling firmJul 15, 20224 x 0.62.4
Class II recall D-0753-2021, this FEI as the recalling firmAug 13, 20214 x 0.251
Class II recall D-0145-2021, this FEI as the recalling firmDec 3, 20204 x 0.251
Class II recall D-0074-2021, this FEI as the recalling firmOct 27, 20204 x 0.251
Class II recall D-0834-2020, this FEI as the recalling firmJan 31, 20204 x 0.251
Class II recall D-1440-2019, this FEI as the recalling firmMay 6, 20194 x 0.251
Class II recall D-1272-2019, this FEI as the recalling firmApr 25, 20194 x 0.251
Class II recall D-0101-2018, this FEI as the recalling firmNov 20, 20174 x 0.251
Class II recall D-1137-2017, this FEI as the recalling firmAug 18, 20174 x 0.251
Class II recall D-1041-2017, this FEI as the recalling firmMay 10, 20174 x 0.251
Class II recall D-0617-2017, this FEI as the recalling firmMar 15, 20174 x 0.251
Class II recall D-0605-2017, this FEI as the recalling firmMar 6, 20174 x 0.251
Class II recall D-1460-2016, this FEI as the recalling firmJul 19, 201610 years or older, so it adds no points0
Class II recall D-1491-2016, this FEI as the recalling firmMay 9, 201610 years or older, so it adds no points0
Class II recall D-0325-2015, this FEI as the recalling firmDec 23, 201410 years or older, so it adds no points0
Class II recall D-0299-2015, this FEI as the recalling firmNov 26, 201410 years or older, so it adds no points0
Class II recall D-0015-2015, this FEI as the recalling firmSep 15, 201410 years or older, so it adds no points0
Class II recall D-0007-2015, this FEI as the recalling firmAug 5, 201410 years or older, so it adds no points0
Class II recall D-1342-2014, this FEI as the recalling firmMay 8, 201410 years or older, so it adds no points0
Class I recall D-838-2013, this FEI as the recalling firmMay 13, 201310 years or older, so it adds no points0
Class II recall D-202-2013, this FEI as the recalling firmMar 5, 201310 years or older, so it adds no points0
Class II recall D-1428-2012, this FEI as the recalling firmMar 14, 201210 years or older, so it adds no points0
Inspection classified VAIFeb 22, 201110 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Zydus Pharmaceuticals (USA) Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Zydus Pharmaceuticals (USA) Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Zydus Pharmaceuticals (USA) Inc
Location
Pennington, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.